AOD-9604 vs Tesamorelin: Which Fat-Targeting Peptide Is Better?

Two Approaches to the Same Problem

Both AOD-9604 and tesamorelin target fat metabolism, but they take fundamentally different paths to get there. Understanding this distinction is critical for choosing between them.

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It stimulates your pituitary gland to release natural growth hormone, which then drives fat metabolism through the normal GH signaling cascade. This means tesamorelin produces the full spectrum of GH-mediated effects: fat breakdown, improved lipid profiles, potential lean mass support, and increased IGF-1 levels.

AOD-9604 takes a surgical approach. It is a synthetic fragment of human growth hormone (amino acids 176-191) that mimics only the fat-burning portion of GH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat creation) without activating the full GH receptor. The result: fat-targeted effects without the broader systemic changes that come with GH axis stimulation.

This difference matters most for two groups. People who want specifically visceral fat reduction with strong clinical backing should lean toward tesamorelin. People who want a lower-cost, lower-systemic-impact option and are comfortable with less clinical data should consider AOD-9604.

The Research Gap

The evidence base for these two peptides is dramatically different, and this should factor heavily into your decision.

Tesamorelin has multiple randomized, placebo-controlled trials in humans. The landmark 2007 study published in the New England Journal of Medicine showed 15% visceral fat reduction over 26 weeks. Subsequent studies have confirmed these results and added data on liver fat reduction (important for NAFLD/MASH), lipid profile improvement, and body composition changes. The FDA found this evidence compelling enough to approve tesamorelin as Egrifta.

AOD-9604's human data is limited. The most cited study is a 2004 Phase 2 trial showing modest weight loss in obese subjects taking oral AOD-9604 over 12 weeks. The results were statistically significant but not dramatic. Most of AOD-9604's compelling data comes from animal studies showing clear lipolytic effects and favorable safety profiles.

This does not mean AOD-9604 is ineffective. Thousands of users report positive fat loss results. But the level of clinical evidence supporting tesamorelin is substantially stronger.

Visceral Fat: Where Tesamorelin Excels

If your primary concern is visceral fat, specifically the deep abdominal fat that wraps around your organs and drives metabolic disease, tesamorelin has a clear advantage.

The clinical data shows tesamorelin specifically and preferentially reduces visceral adipose tissue. This is not general weight loss. CT scans in clinical trials demonstrated selective visceral fat reduction even when total body weight did not change dramatically. For people with metabolic syndrome, insulin resistance, or elevated cardiovascular risk from central adiposity, this targeted effect is medically significant.

AOD-9604 promotes general lipolysis without published evidence of preferential visceral fat targeting. It may reduce overall body fat, but the clinical proof for visceral-specific action is not there.

The IGF-1 Question

One of the most important practical differences between these peptides is their effect on IGF-1 (insulin-like growth factor 1).

Tesamorelin increases IGF-1 because it stimulates real GH release. Elevated IGF-1 levels require monitoring because sustained high IGF-1 is associated with increased cancer risk in some epidemiological studies. Most physicians prescribing tesamorelin will check IGF-1 levels at baseline and every 3-6 months.

AOD-9604 does not increase IGF-1. This is its key safety advantage. Because it only activates the lipolytic fragment of GH signaling, it bypasses the IGF-1 pathway entirely. For people who are concerned about long-term GH axis stimulation or who have a family history of IGF-1 sensitive conditions, this is a meaningful differentiator.

Cost and Accessibility

The cost difference is substantial. AOD-9604 is available through research peptide vendors at $50-150 per month. Tesamorelin, especially brand-name Egrifta, can run $300-600 or more per month. Compounded tesamorelin from specialty pharmacies is less expensive but still typically more than AOD-9604.

Both require daily subcutaneous injection. Neither is available orally in effective forms (though AOD-9604 was tested orally in one clinical trial, the results were modest compared to injectable protocols reported in community use).

Stacking Considerations

These two peptides should generally not be stacked together. Tesamorelin already produces lipolytic effects through GH release, and adding AOD-9604 creates redundancy without clear additive benefit.

Better stacking options:

• Tesamorelin + MOTS-c: Visceral fat reduction plus mitochondrial metabolic optimization. Complementary mechanisms with no overlap. See the Fat Loss Stack for a complete protocol.
• AOD-9604 + CJC-1295/ipamorelin: If you want GH optimization benefits alongside AOD-9604's targeted lipolysis, pair it with GH secretagogues. The GH secretagogues provide the broader benefits while AOD-9604 amplifies the fat-targeting component.
• Either compound + semaglutide or tirzepatide: GLP-1 medications handle appetite suppression. Fat-targeting peptides address the metabolic side. This combination attacks fat loss from both behavioral (eating less) and metabolic (burning more) angles.

Who Should Choose Which

Choose tesamorelin if: You have significant visceral fat, want the strongest clinical evidence, can afford the higher cost, and are willing to monitor IGF-1 levels. Particularly relevant for people with metabolic syndrome, NAFLD, or HIV-associated lipodystrophy.

Choose AOD-9604 if: You want an affordable fat-targeting peptide, prefer to avoid IGF-1 elevation, are comfortable with limited but promising clinical data, or are stacking with other GH-axis peptides and want to add lipolysis without redundant GH stimulation.